United States - English - NLM (National Library of Medicine)

taro pharmaceuticals u.s.a., inc. - iloperidone (unii: vpo7kj050n) (iloperidone - unii:vpo7kj050n) - iloperidone tablets are indicated for the treatment of schizophrenia in adults. when deciding among the alternative treatments available for this condition, the prescriber should consider the finding that iloperidone tablets are associated with prolongation of the qtc interval [see warnings and precautions (5.3)] . prolongation of the qtc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia which can result in sudden death. in many cases this would lead to the conclusion that other drugs should be tried first. whether iloperidone tablets will cause torsade de pointes or increase the rate of sudden death is not yet known. patients must be titrated to an effective dose of iloperidone tablets. thus, control of symptoms may be delayed during the first 1 to 2 weeks of treatment compared to some other antipsychotic drugs that do not require a similar titration. prescribers should be mindful of this delay when

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - iloperidone (unii: vpo7kj050n) (iloperidone - unii:vpo7kj050n) - iloperidone 1 mg - iloperidone tablets are indicated for the treatment of schizophrenia in adults. when deciding among the alternative treatments available for this condition, the prescriber should consider the finding that iloperidone is associated with prolongation of the qtc interval [see warnings and precautions (5.3)] . prolongation of the qtc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia which can result in sudden death. in many cases this would lead to the conclusion that other drugs should be tried first. whether iloperidone tablets will cause torsade de pointes or increase the rate of sudden death is not yet known. patients must be titrated to an effective dose of iloperidone tablets. thus, control of symptoms may be delayed during the first 1 to 2 weeks of treatment compared to some other antipsychotic drugs that do not require a similar titration. prescribers should be mindful of this delay when selecti

United States - English - NLM (National Library of Medicine)

vanda pharmaceuticals inc. - iloperidone (unii: vpo7kj050n) (iloperidone - unii:vpo7kj050n) - iloperidone 1 mg - fanapt®  is indicated for the treatment of schizophrenia in adults. when deciding among the alternative treatments available for this condition, the prescriber should consider the finding that fanapt is associated with prolongation of the qtc interval [see (warnings and precautions 5.3)] . prolongation of the qtc interval is associated in some other drugs with the ability to cause torsade de pointes­ type arrhythmia, a potentially fatal polymorphic ventricular tachycardia which can result in sudden death. in many cases this would lead to the conclusion that other drugs should be tried first. whether fanapt will cause torsade de pointes or increase the rate of sudden death is not yet known. patients must be titrated to an effective dose of fanapt. thus, control of symptoms may be delayed during the first 1 to 2 weeks of treatment compared to some other antipsychotic drugs that do not require a similar titration. prescribers should be mindful of this delay when selecting an antipsychotic drug for the treatment

United States - English - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - iloperidone (unii: vpo7kj050n) (iloperidone - unii:vpo7kj050n) - iloperidone 1 mg

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - iloperidone (unii: vpo7kj050n) (iloperidone - unii:vpo7kj050n) - iloperidone 4 mg - fanapt®  tablets are indicated for the treatment of adults with schizophrenia. efficacy was established in two short-term (4- and 6-week) placebo-and active-controlled studies of adult patients with schizophrenia [see clinical studies (14)] . when deciding among the alternative treatments available for this condition, the prescriber should consider the finding that fanapt is associated with prolongation of the qtc interval [see warnings and precautions (5.2)] . prolongation of the qtc interval is associated in some other drugs with the ability to cause torsade de pointes-type arrhythmia, a potentially fatal polymorphic ventricular tachycardia which can result in sudden death. in many cases this would lead to the conclusion that other drugs should be tried first. whether fanapt will cause torsade de pointes or increase the rate of sudden death is not yet known. patients must be titrated to an effective dose of fanapt. thus, control of symptoms may be delayed during the first 1 to 2 weeks of treatment compared

Israel - English - Ministry of Health

megapharm ltd - iloperidone - tablets - iloperidone 1 mg - iloperidone - iloperidone - fanapt is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.

Israel - English - Ministry of Health

megapharm ltd - iloperidone - tablets - iloperidone 2 mg - iloperidone - iloperidone - fanapt is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.

Israel - English - Ministry of Health

megapharm ltd - iloperidone - tablets - iloperidone 4 mg - iloperidone - iloperidone - fanapt is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.

Israel - English - Ministry of Health

megapharm ltd - iloperidone - tablets - iloperidone 6 mg - iloperidone - iloperidone - fanapt is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.

Israel - English - Ministry of Health

megapharm ltd - iloperidone - tablets - iloperidone 8 mg - iloperidone - iloperidone - fanapt is an atypical antipsychotic agent indicated for the treatment of schizophrenia in adults.